Abstract: |
Surgery is the treatment of choice for lentigo maligna (LM) and lentigo maligna melanoma (LMM). However, not all patients are good surgical candidates for reasons such as large lesion size, anatomically sensitive location, medical comorbidities, or patient preference. Non-surgical treatment options include topical imiquimod, topical retinoids, cryotherapy, elecrodessication and curettage, ablative CO2 laser, and radiation therapy. Off-label use of topical imiquimod for lentigo maligna type melanoma in situ has been reported in the literature since 2000 [1]. Studies are limited to small series with short follow up [1-5]. Two LM cases are presented to illustrate treatment challenges with topical imiquimod and variability of treatment response. © Springer International Publishing Switzerland 2017. |